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Background
The phase 1 study of nivolumab, a fully human IgG4
programmed death-1 (PD-1) immune checkpoint inhibi-
tor monoclonal antibody, showed promising antitumor
activity in patients with advanced melanoma.
Materials and methods
This phase 3 study compared nivolumab vs dacarbazine in
treatment-naïve patients with BRAF wild-type metastatic
melanoma. Patients were randomized 1:1 to receive nivo-
lumab 3 mg/kg every 2 weeks (Q2W) + placebo Q3W
(n = 210) or dacarbazine 1000 mg/m2 Q3W + placebo
Q2W (n = 208) until disease progression or unacceptable
toxicity. Randomization was stratified by M-stage and pro-
grammed death ligand-1 (PD-L1) status. The primary end-
point was overall survival (OS). Patients were followed for
up to 16.7 months at the time of data cutoff, which
occurred 5.2 months after the first visit of the last patient
randomized.
Results
The hazard ratio (HR) for death was 0.42 (99.79% CI
0.25–0.73; P < 0.0001) in favor of nivolumab, with 1-
year OS rate 73% (95% CI, 66%–79%) for nivolumab vs
42% (95% CI, 33%–51%) for dacarbazine. Median OS
was not reached for nivolumab and was 10.8 months
for dacarbazine. Median progression-free survival (PFS)
was 5.1 months for nivolumab and 2.2 months for
dacarbazine (HR for death or progression 0.43, 95% CI
0.34–0.56; P < 0.0001). Objective response rate was
40% (84/210) vs 14% (29/208) for nivolumab and
dacarbazine, respectively (P < 0.0001). Median duration
of response was not reached for nivolumab and
6 months for dacarbazine. At the time of data cutoff,
responses were ongoing in 86% (72/84) of nivolumab
and 52% (15/29) of dacarbazine responders. PD-L1
positivity (using a 5% tumor cell surface staining cut-
off) appeared to be associated with improved OS in the
nivolumab arm (85% of PD-L1+ and 71% of PD-L1-/
indeterminate patients alive at the time of last follow-
up). Both PD-L1+ and PD-L1-/indeterminate patients
receiving nivolumab had improved OS vs dacarbazine
(un-stratified HR 0.30, 95% CI, 0.15–0.60 in PD-L1+
patients; 0.48, 95% CI, 0.32–0.71 in PD-L1-/indetermi-
nate patient, both in favor of the nivolumab arm). The
most common nivolumab-related adverse events (AEs)
were fatigue, pruritus, and nausea. Drug-related grade
3–4 AEs were reported in 12% vs 18% of patients
receiving nivolumab vs dacarbazine, respectively. AEs
led to discontinuation in 7% and 12% of dacarbazine-
vs nivolumab-treatment patients, respectively.
Conclusions
Compared to dacarbazine, nivolumab significantly
improved OS and PFS in previously untreated patients
with BRAF wild-type metastatic melanoma with an
acceptable safety profile.
Clinical Trial Registration Number
NCT01721772.
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